期刊文献+

Expressions and clinical significances of MMP-2 and TIMP-2 mRNA in bladder transitional cell carcinomas

膀胱癌组织中MMP-2与TIMP-2 mRNA的表达及临床意义(英文)
下载PDF
导出
摘要 Objective:The aim of the study was to investigate the expressions of matrix metalloproteinase-2(MMP-2) and tissue inhibitor of MMP-2(TIMP-2) mRNA in transitional cell carcinomas of bladder and discuss their clinical significances.Methods:Using RT-PCR and real time quantitative PCR(RQ-PCR) technique,the expressions of MMP-2 and TIMP-2 mRNA of 45 cases of bladder carcinoma(tumor group) and 10 cases of normal bladder tissue(control group) were analyzed.Results:MMP-2 and TIMP-2 were not expressed in control group.MMP-2 was expressed in 30 cases tumor samples and TIMP-2 was expressed in 26 cases.The expression of MMP-2 mRNA in non-muscle invasive bladder cancers and grade I cancers was lower than that in muscle invasive bladder cancers and grades II-III cancers respectively.The differences were statistically significant(P<0.05).The expression of MMP-2 in recurrent patients was higher than that in incipient patients.TIMP-2 mRNA expression decreased with grades and stage.The expression of TIMP-2 in non-muscle invasive bladder cancers and grade I cancers was higher than that in muscle invasive bladder cancers and grades II-III cancers respectively.There was statistical difference between two groups(P < 0.05).TIMP-2 expression in incipient patients was higher than that in recurrent patients,but the difference was not significant(P>0.05).Conclusion:These results suggest that MMP-2 and TIMP-2 play an important role in the invasion step of transitional cell carcinoma of bladder.MMP-2 may become a new approach to the diagnosis of bladder carcinoma.
出处 《The Chinese-German Journal of Clinical Oncology》 CAS 2011年第5期278-281,共4页 中德临床肿瘤学杂志(英文版)
关键词 transitional cell carcinoma of bladder matrix metalloproteinase-2(MMP-2) tissue inhibitor of MMP-2(TIMP-2) MMP 膀胱癌 临床意义 癌基因 细胞 移行 实时定量PCR mRNA表达
  • 相关文献

参考文献16

  • 1Sharma S,Ksheersagar P,Sharma P.Diagnosis and treatment of bladder cancer.Am Fam Physician,2009,80:717–723.
  • 2Bischoff CJ,Clark PE.Bladder cancer.Curr Opin Oncol,2009,21:272–277.
  • 3Mitra AP,Cote RJ.Molecular screening for bladder cancer:progress and potential.Nat Rev Urol,2010,7:11–20.
  • 4Martin MD,Matrisian LM.The other side of MMPs:protective roles in tumor progression.Cancer Metastasis Rev,2007,26:717–724.
  • 5Seo DW,Li H,Guedez L,et al.TIMP-2 mediated inhibition of angiogenesis:an MMP-independent mechanism.Cell,2003,114:171–180.
  • 6Ghavamian R,Hakimi AA.Lymph node dissection for bladder cancer:the issue of extent and feasibility in the minimally invasive era.Expert Rev Anticancer Ther,2009,9:1783–1792.
  • 7Lombard C,Saulnier J,Wallach J.Assays of matrix metalloproteinases (MMPs) activities:a review.Biochimie,2005,87:265–272.
  • 8Turpeenniemi-Hujanen T.Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers.Biochimie,2005,87:287–297.
  • 9Vasala K,P(a)(a)kk(a) P,Turpeenniemi-Hujanen T.Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer.Urology,2003,62:952–957.
  • 10Kawamura K,Kamiya N,Suyama T,et al.In situ gelatinolytic activity correlates with tumor progression and prognosis in patients with bladder cancer.J Urol,2004,172:1480–1484.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部